Xu Gang, Yang Fang, Ding Cui-Ling, Zhao Lan-Juan, Ren Hao, Zhao Ping, Wang Wen, Qi Zhong-Tian
Department of Microbiology, Shanghai Key Laboratory of Medical Biodefense, Second Military Medical University, 800 XiangYin RD, Shanghai 200433, China.
Mol Cancer. 2014 Sep 14;13:216. doi: 10.1186/1476-4598-13-216.
Emerging evidence suggests that small nucleolar RNAs (snoRNAs) are involved in tumorigenesis. The roles of small nucleolar RNA 113-1 (SNORD113-1) on the development of hepatocellular carcinoma (HCC) remain unknown.
The expression of SNORD113-1 was measured in 112 HCC tumor tissues using quantitative RT-PCR and compared with expression levels from with paired non-tumor tissues. The effects of SNORD113-1 on HCC tumorigenesis were investigated in HepG2 and Huh7 cells as well as a xenograft nude mouse model. CpG methylation within the promoter region of the SNORD113-1 gene was identified using Sodium bisulfite sequencing. Cancer pathway reporter investigate the mechanism by which SNORD113-1 suppressed tumorigenesis.
SNORD113-1 expression was significantly downregulated in HCC tumors compared with adjacent non-tumor tissues, and downregulation of SNORD113-1 in HCC tumors was significantly associated with worse survival of patients. In addition, CpG methylation at the promoter region of the SNORD113-1 gene was higher in HCC tumors than adjacent non-tumor tissues. Functionally, SNORD113-1 suppressed cancer cell growth in HepG2 and Huh7 cells and in a xenograft nude mouse model. Furthermore, SNORD113-1 inactivated the phosphorylation of ERK1/2 and SMAD2/3 in MAPK/ERK and TGF-β pathways.
SNORD113-1 functions as a tumor suppressor role in HCC and may be important as a potential diagnostic and therapeutic target for HCC.
新出现的证据表明,小核仁RNA(snoRNAs)参与肿瘤发生。小核仁RNA 113-1(SNORD113-1)在肝细胞癌(HCC)发展中的作用尚不清楚。
使用定量逆转录PCR检测112例HCC肿瘤组织中SNORD113-1的表达,并与配对的非肿瘤组织的表达水平进行比较。在HepG2和Huh7细胞以及异种移植裸鼠模型中研究SNORD113-1对HCC肿瘤发生的影响。使用亚硫酸氢钠测序鉴定SNORD113-1基因启动子区域内的CpG甲基化。癌症通路报告基因研究SNORD113-1抑制肿瘤发生的机制。
与相邻的非肿瘤组织相比,HCC肿瘤中SNORD113-1表达显著下调,HCC肿瘤中SNORD113-1的下调与患者较差的生存率显著相关。此外,HCC肿瘤中SNORD113-1基因启动子区域的CpG甲基化高于相邻的非肿瘤组织。在功能上,SNORD113-1抑制HepG2和Huh7细胞以及异种移植裸鼠模型中的癌细胞生长。此外,SNORD113-1使MAPK/ERK和TGF-β通路中ERK1/2和SMAD2/3的磷酸化失活。
SNORD113-1在HCC中起肿瘤抑制作用,可能作为HCC潜在的诊断和治疗靶点具有重要意义。